Last reviewed · How we verify
Vantictumab combined with paclitaxel — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Vantictumab combined with paclitaxel (Vantictumab combined with paclitaxel) — OncoMed Pharmaceuticals, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Vantictumab combined with paclitaxel TARGET | Vantictumab combined with paclitaxel | OncoMed Pharmaceuticals, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Vantictumab combined with paclitaxel CI watch — RSS
- Vantictumab combined with paclitaxel CI watch — Atom
- Vantictumab combined with paclitaxel CI watch — JSON
- Vantictumab combined with paclitaxel alone — RSS
Cite this brief
Drug Landscape (2026). Vantictumab combined with paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/vantictumab-combined-with-paclitaxel. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab